Throughout its history, Corning has focused on research and development — empowering our leading scientists and engineers to develop solutions to problems that matter. In October 2019, the company announced that a leading pharmaceutical manufacturer received FDA approval of Corning Valor? Glass for use as a new primary package for a marketed drug product.
Our development of this innovative packaging solution builds on over a century and a half of groundbreaking work in glass. Whether it’s Dr. Jonas Salk’s use of our PYREX? vessels to help produce his life-saving polio vaccine, or the invention of low-loss optical fiber that ushered in the Information Age with previously unimaginable connectivity, Corning product developments have focused on meeting our customer challenges and improving, and often enabling, healthier lives.
In the quest to build a better pharmaceutical glass container, Corning’s experience and expertise has made it uniquely positioned to take on this challenge. “Corning exists to transform and optimize this ancient material for advanced, modern applications,” explains Jeff Evenson, Corning executive vice president and chief strategy officer.
Our first question before starting work on any new innovation is “why?” What is the need and how do we hope to solve it? When we thought about the glass containers that have been used in the pharmaceutical industry for years, we knew that this conventional borosilicate glass was invented in the 1800s for general glassware use. It was simply adopted by the pharmaceutical industry, not specifically designed for its needs. Simply put, as drug therapies have advanced, the glass containers they are stored and transported in, and administered from, have largely stayed the same. Ultimately, the needs of the pharmaceutical industry have evolved. It was time for a better glass.